The 3/31/16 pro forma cash balance was $388.2M; this consisted of: $345.8M of unrestricted cash and marketable securities; $21.7M of collaboration receivables from MYL relating to the companies’ FoB partnership; and $20.7M of restricted cash (mostly related to the Lovenox patent case).
For the remaining nine months of 2016, MNTA’s cash-usage guidance—excluding all revenue from NVS and BXLT, but taking into account R&D reimbursement from MYL—is $120-135M (i.e. $40-45M per quarter).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.